Reported Earlier, HUTCHMED Reports Late-Stage Results For New Lung Cancer Treatment Combo
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic
HUTCHMED tested a new medicine combo to help people with advanced lung cancer and got good results from a big study. When a drug company shows strong test results, it's a sign their science might work, so watch whether doctors and regulators agree it's ready to use.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.